
Quarterly report 2023-Q1
added 05-15-2023
Invacare Corporation EBITDA 2011-2026 | IVC
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Invacare Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -65 M | -7.41 M | 25.6 M | 26.5 M | 1.33 M | -12.9 M | -5.52 M | 12.4 M | -3.74 M | 12.4 M | 69 M | 111 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 111 M | -65 M | 13.6 M |
Quarterly EBITDA Invacare Corporation
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -6.88 M | - | -21.6 M | -6.95 M | -12.7 M | - | -12.3 M | 4.77 M | -1.66 M | - | 13.3 M | -2.24 M | 13.9 M | - | 14.2 M | 3.3 M | -580 K | - | 6.7 M | 939 K | -1.04 M | - | 5.07 M | -8.37 M | -7.06 M | - | 13.5 M | 1.45 M | -1.42 M | - | 13.8 M | 4.62 M | 968 K | - | 26.4 M | 18.2 M | 9.51 M | - | 28.2 M | 18.9 M | 8.85 M | - | 29.1 M | 19.4 M | 9.63 M | - | 27.6 M | 18.1 M | 8.8 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 29.1 M | -21.6 M | 6.39 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical devices industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Alphatec Holdings
ATEC
|
-4.64 M | $ 11.9 | -2.06 % | $ 1.79 B | ||
|
Butterfly Network
BFLY
|
-65.5 M | $ 4.29 | 2.39 % | $ 908 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
-3.98 M | - | - | $ 1.77 B | ||
|
Axonics Modulation Technologies
AXNX
|
-53.2 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
-24.1 M | - | 1.37 % | $ 20.5 M | ||
|
Acutus Medical
AFIB
|
-11.5 M | - | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
-815 K | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
-9.8 M | - | -5.86 % | $ 30.6 M | ||
|
BioSig Technologies
BSGM
|
-12.7 M | - | 37.08 % | $ 85.7 M | ||
|
LivaNova PLC
LIVN
|
228 M | $ 62.99 | -0.4 % | $ 3.44 B | ||
|
Conformis
CFMS
|
-42.2 M | - | - | $ 16.4 M | ||
|
LENSAR
LNSR
|
-7.7 M | $ 5.72 | -5.85 % | $ 65.9 M | ||
|
Cardiovascular Systems
CSII
|
-32.1 M | - | 0.15 % | $ 844 M | ||
|
IRIDEX Corporation
IRIX
|
-8.91 M | $ 1.35 | -0.22 % | $ 21.8 M | ||
|
Apollo Endosurgery
APEN
|
-30.2 M | - | - | $ 475 M | ||
|
Medtronic PLC
MDT
|
8.82 B | $ 87.15 | -0.07 % | $ 112 B | ||
|
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | ||
|
CryoLife, Inc.
CRY
|
23.2 M | - | -4.14 % | $ 702 M | ||
|
AxoGen
AXGN
|
-1.19 M | $ 32.23 | 1.51 % | $ 1.48 B | ||
|
CONMED Corporation
CNMD
|
120 M | $ 36.47 | -0.44 % | $ 1.13 B | ||
|
Soliton, Inc.
SOLY
|
-14.1 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
88.4 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-8.53 M | - | 0.03 % | $ 1.58 B | ||
|
Electromed
ELMD
|
10.7 M | $ 24.44 | -0.2 % | $ 207 M | ||
|
Misonix, Inc.
MSON
|
-15.9 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M | ||
|
Intersect ENT, Inc.
XENT
|
-64.8 M | - | - | $ 955 M | ||
|
Cytosorbents Corporation
CTSO
|
-15.2 M | $ 0.68 | 0.86 % | $ 37 M | ||
|
Aethlon Medical
AEMD
|
-9 M | $ 2.24 | -2.61 % | $ 3.5 M | ||
|
BIOLASE
BIOL
|
-15.1 M | - | -13.19 % | $ 166 K | ||
|
Orthofix Medical
OFIX
|
-4.11 M | $ 11.9 | 0.25 % | $ 471 M | ||
|
AdaptHealth Corp.
AHCO
|
473 M | $ 11.04 | 6.41 % | $ 1.49 B | ||
|
Myomo
MYO
|
-13.5 M | $ 0.72 | 2.1 % | $ 30.1 M | ||
|
IRadimed Corporation
IRMD
|
27.3 M | $ 99.94 | 0.75 % | $ 1.27 B | ||
|
Nano-X Imaging Ltd.
NNOX
|
-61 M | $ 2.36 | -3.28 % | $ 138 M | ||
|
EDAP TMS S.A.
EDAP
|
-18 M | $ 3.85 | 3.08 % | $ 144 M | ||
|
OrthoPediatrics Corp.
KIDS
|
-18.1 M | $ 16.26 | -1.28 % | $ 381 M | ||
|
Penumbra
PEN
|
207 M | $ 335.06 | -0.15 % | $ 13 B | ||
|
Outset Medical
OM
|
-62.4 M | $ 3.51 | -3.04 % | $ 53.4 K | ||
|
Inspire Medical Systems
INSP
|
64.9 M | $ 51.85 | -0.69 % | $ 1.52 B | ||
|
Insulet Corporation
PODD
|
564 M | $ 225.55 | -0.68 % | $ 15.9 B | ||
|
Profound Medical Corp.
PROF
|
-30.3 M | $ 5.16 | -4.44 % | $ 180 M | ||
|
Pulmonx Corporation
LUNG
|
-52.6 M | $ 1.38 | -1.08 % | $ 56.1 M | ||
|
Quanterix Corporation
QTRX
|
-110 M | $ 3.75 | -4.82 % | $ 160 M | ||
|
Cutera
CUTR
|
-148 M | - | -10.19 % | $ 1.99 M | ||
|
Dynatronics Corporation
DYNT
|
-1.97 M | - | 14.99 % | $ 929 K | ||
|
InspireMD
NSPR
|
426 M | $ 1.79 | 3.47 % | $ 115 M |